Strides Pharma's Cinacalcet Tablets Recalled Nationwide Due to Failed Dissolution Specifications
Strides Pharma, Inc. has initiated a nationwide Class II recall of 6,672 bottles of Cinacalcet Tablets 90 mg (Lot #: 7715893A) due to critical failed dissolution specifications. This action, stemming from product manufactured by Strides Pharma Science Ltd. in India, poses immediate supply chain risks for procurement directors and regulatory challenges for quality assurance teams. Businesses must assess their reliance on Strides' Cinacalcet supply and evaluate potential sourcing alternatives to mitigate disruption.
FDA Class II Recall: Strides Pharma's Cinacalcet Fails Dissolution Specifications
Strides Pharma, Inc., based in Chestnut Ridge, NY, has initiated a Class II recall, designated D-0546-2025, for its Cinacalcet Tablets 90 mg. The recall commenced on July 9, 2025, and is currently ongoing, impacting 6,672 bottles of the 30-count product from Lot #: 7715893A, with an expiration date of December 31, 2027. The primary reason for this nationwide recall within the United States is the product's failure to meet dissolution specifications. For procurement directors, this immediately signals a potential disruption in the supply of a critical medication. Regulatory affairs heads must recognize that failed dissolution directly compromises drug bioavailability and efficacy, posing risks to patient treatment for hyperparathyroidism. The Class II classification indicates that the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote, yet it underscores a significant lapse in quality control. Supply chain VPs must swiftly assess their inventory and distribution networks to prevent stock-outs and ensure continuous patient access to compliant alternatives. Business development executives should view this as a potential market opportunity for competitors offering compliant Cinacalcet formulations.
Global Manufacturing and Distribution Network for Cinacalcet
The recalled Cinacalcet Tablets, distributed by Strides Pharma, Inc. from Chestnut Ridge, NY, were manufactured by Strides Pharma Science Ltd. in Puducherry, India. This dual-entity structure highlights the complexities inherent in global pharmaceutical supply chains. Cinacalcet Hydrochloride, an oral human prescription drug with ANDA209226, is primarily utilized in the management of hyperparathyroidism. For procurement teams, this setup means that while the U.S. entity manages the recall logistics, the fundamental quality issue and subsequent corrective actions must originate from the Indian manufacturing facility. This necessitates stringent oversight and auditing of overseas partners. Regulatory affairs teams must ensure that the quality management systems at the Puducherry facility are robust enough to prevent recurrence, as FDA scrutiny extends to international manufacturing sites supplying the U.S. market. Supply chain VPs must integrate geographical distance and varying regulatory frameworks into their risk assessments, understanding that reliance on a single international manufacturing source for essential medicines like Cinacalcet can introduce significant vulnerabilities and increase the lead time for issue resolution.
Supply Chain Exposure: Mitigating Disruption for Cinacalcet
The nationwide distribution of 6,672 bottles of Cinacalcet Tablets 90 mg affected by this recall creates an immediate supply gap across the United States. Cinacalcet is a vital medication for patients managing hyperparathyroidism, a condition frequently associated with chronic kidney disease. Procurement directors must promptly quantify their exposure to the specific Lot #: 7715893A and evaluate their broader dependency on Strides Pharma for Cinacalcet. While a Class II recall is not the most severe, it mandates the removal of affected product from the market, directly impacting existing inventory and potentially leading to localized shortages. Supply chain VPs need to activate robust contingency plans, prioritizing transparent communication with downstream pharmacies, hospitals, and group purchasing organizations to manage expectations and facilitate the efficient return of non-compliant product. Business development executives should closely monitor the competitive landscape, as this disruption could trigger shifts in market share towards other manufacturers of Cinacalcet or its therapeutic alternatives. Regulatory affairs teams are tasked with ensuring that any replacement product sourced adheres to all FDA quality and dissolution standards to prevent similar compliance issues.
Alternative Suppliers: Diversifying Your Cinacalcet Sourcing Strategy
The ChemLifeIntel Knowledge Graph does not currently identify specific alternative suppliers for Cinacalcet Hydrochloride. This absence of readily available alternatives underscores a critical challenge for procurement directors impacted by this recall. Businesses must proactively identify and qualify new sources to diversify their supply chain. This process involves researching other ANDA holders for Cinacalcet—information often found in the FDA's Orange Book—and rigorously evaluating their manufacturing capabilities, regulatory compliance history, and geographic footprint. Qualification timelines for new suppliers can be extensive, frequently spanning several months, which highlights the urgency of initiating this process immediately. Regulatory affairs heads must ensure that any prospective supplier's product meets all specifications, including dissolution, and that their facilities undergo thorough audits. Supply chain VPs should prioritize suppliers demonstrating robust quality systems and a consistent track record of FDA compliance to minimize future supply disruptions and mitigate regulatory risks.
Strides Pharma's Regulatory Compliance Record and Increased Scrutiny
The ChemLifeIntel Knowledge Graph does not contain specific prior regulatory actions or a history of compliance issues for Strides Pharma, Inc. or its manufacturing arm, Strides Pharma Science Ltd. Despite the absence of a documented history of past violations, this Class II recall for failed dissolution specifications represents a significant regulatory event for the company. For regulatory affairs heads, this incident will almost certainly trigger heightened scrutiny from the FDA regarding Strides Pharma's quality management systems, particularly at the manufacturing site in Puducherry, India. Procurement directors should interpret this recall as a critical indicator, prompting a deeper investigation into the supplier's overall quality metrics, internal audit reports, and corrective action capabilities, even in the absence of a public record of past infractions. Business development executives must be aware that such regulatory events can negatively impact a company's reputation and its ability to secure new contracts or expand into new markets, potentially affecting long-term partnerships and investor confidence.
Remediation Timeline and Future Regulatory Outlook for Strides Pharma
The recall (D-0546-2025) remains in an "Ongoing" status, indicating that Strides Pharma, Inc. is actively engaged in removing the affected Cinacalcet product from the U.S. market. Concurrently, the manufacturing entity, Strides Pharma Science Ltd. in India, is expected to conduct a comprehensive root cause analysis into the failed dissolution specifications and implement robust corrective and preventive actions (CAPA). For regulatory affairs teams, closely monitoring the FDA's oversight of Strides' CAPA plan is paramount. A failure to adequately address the underlying quality issues could lead to further regulatory enforcement, including additional recalls, the issuance of a Warning Letter, or even an Import Alert for products originating from the Puducherry facility. Procurement directors should anticipate potential delays in future shipments of Cinacalcet from Strides if the remediation process is protracted or if the FDA deems the CAPA insufficient. Supply chain VPs must integrate this inherent uncertainty into their long-term forecasting and supplier diversification strategies, recognizing that resolving significant quality issues can demand substantial time and resources, impacting market availability.